文献速递消化道肿瘤放疗胸部肿瘤放疗

新辅助放疗联合氟尿嘧啶-顺铂及西妥昔单抗治疗可手术局部晚期食管癌:I-II期试验(FFCD-0505/PRODIGE-3)结果

Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3).
PubMed 文献 · Clin Transl Radiat Oncol · 2024-06-09

该I-II期试验旨在确定放化疗联合西妥昔单抗的最佳剂量及病理完全缓解率。I期确定5FU-顺铂联合西妥昔单抗的最大耐受剂量,II期旨在显示pCR率>20%。结果显示pCR率为18.5%(5/27),未达到预设的>20%标准;中位无进展生存期13.7个月,中位总生存期未达到。结论认为加用西妥昔单抗毒性增加且未达到pCR>20%的要求,可能与化疗剂量强度降低有关。

要点

  • I期确定推荐剂量:西妥昔单抗每周400 mg/m2(放疗前一周)和250 mg/m2(放疗期间);5FU 500 mg/m2/天 d1-d4联合顺铂40 mg/m2 d1,第1周和第5周给药。
  • II期部分32例患者接受术前放化疗,31例接受手术,27例实现切除,其中5例(18.5%)达到病理完全缓解(ypT0Nx)。
  • 中位随访19个月,中位无进展生存期13.7个月,中位总生存期未达到。

核心结论

  • 术前放化疗加用西妥昔单抗具有毒性,且未达到要求的pCR>20%。
  • I期确定的推荐剂量可能因降低化疗剂量强度而导致令人失望的结果。

研究设计与样本

  • I-II期试验,I期确定5FU-顺铂联合西妥昔单抗的剂量限制性毒性和最大耐受剂量,II期旨在显示pCR率>20%(预期25%),需33例患者(I期6例加II期27例)。
  • 放疗方案为45 Gy/5周。

主要发现

  • II期部分32例患者接受术前放化疗,31例接受手术,27例实现切除。
  • 27例中5例(18.5%)达到病理完全缓解(ypT0Nx)。
  • 中位随访19个月,中位无进展生存期13.7个月,中位总生存期未达到。

关键数值与推荐

  • I期确定的推荐剂量:西妥昔单抗每周400 mg/m2(放疗前一周)和250 mg/m2(放疗期间);5FU 500 mg/m2/天 d1-d4联合顺铂40 mg/m2 d1,第1周和第5周给药。
  • 病理完全缓解定义为ypT0Nx。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Radiotherapy combined with fluorouracil (5FU) and cisplatin for locally advanced esophageal cancer is associated with a 20-25% pathologic complete response (pCR) rate. Cetuximab increases the efficacy of radiotherapy in patients with head and neck carcinomas. The aim of this phase I/II trial was to determine the optimal doses and the pCR rate with chemoradiotherapy (C-RT) plus cetuximab. METHODS: A 45-Gy radiotherapy regimen was delivered over 5 weeks. The phase I study determined the dose-limiting toxicity and the maximum tolerated dose of 5FU-cisplatin plus cetuximab. The phase II trial aimed to exhibit a pCR rate > 20 % (25 % expected), requiring 33 patients (6 from phase I part plus 27 in phase II part). pCR was defined as ypT0Nx. RESULTS: The phase I study established the following recommended doses: weekly cetuximab (400 mg/m2 one week before, and 250 mg/m2 during radiotherapy); 5FU (500 mg/m2/day, d1-d4) plus cisplatin (40 mg/m2, d1) during week 1 and 5. In the phase II part, 32 patients received C-RT before surgery, 31 patients underwent surgery, and resection was achieved in 27 patients. A pCR was achieved in five patients (18.5 %) out of 27. After a median follow-up of 19 months, the median progression-free survival was 13.7 months, and the median overall survival was not reached. CONCLUSIONS: Adding cetuximab to preoperative C-RT was toxic and did not achieve a pCR > 20 % as required. The recommended doses, determined during the phase I part, could explain these disappointing results due to a reduction in chemotherapy dose-intensity. TRIAL REGISTRATION: This trial was registered with EudraCT number 2006-004770-27.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. de Rauglaudre B, Piessen G, Jary M, et al. Neoadjuvant radiotherapy combined with fluorouracil-cisplatin plus cetuximab in operable, locally advanced esophageal carcinoma: Results of a phase I-II trial (FFCD-0505/PRODIGE-3). Clin Transl Radiat Oncol. 2024. PMID: 38974185. doi:10.1016/j.ctro.2024.100804

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。